William Blair Investment Management LLC Invests $61.27 Million in Establishment Labs Holdings Inc. $ESTA

William Blair Investment Management LLC bought a new position in Establishment Labs Holdings Inc. (NASDAQ:ESTA) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 714,051 shares of the company’s stock, valued at approximately $61,273,000. William Blair Investment Management LLC owned approximately 2.40% of Establishment Labs at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of the business. BlackRock Inc. acquired a new position in Establishment Labs in the second quarter valued at approximately $135,752,000. Rice Hall James & Associates LLC acquired a new position in Establishment Labs during the 2nd quarter valued at about $48,134,000. Goldman Sachs Group Inc. raised its holdings in Establishment Labs by 117.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 811,536 shares of the company’s stock worth $59,145,000 after purchasing an additional 438,206 shares in the last quarter. Viking Global Investors LP bought a new stake in shares of Establishment Labs in the 2nd quarter worth $14,669,000. Finally, Soleus Capital Management L.P. bought a new stake in Establishment Labs in the second quarter worth about $9,050,000. 72.91% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on ESTA shares. JPMorgan Chase & Co. increased their price objective on Establishment Labs from $84.00 to $95.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Citigroup raised shares of Establishment Labs from a “neutral” rating to a “buy” rating and set a $92.00 price objective on the stock in a research report on Thursday, August 13th. Weiss Ratings restated a “sell (e+)” rating on shares of Establishment Labs in a research note on Wednesday, June 24th. Canaccord Genuity Group set a $105.00 price target on shares of Establishment Labs in a research note on Thursday, August 6th. Finally, BTIG Research increased their price objective on Establishment Labs from $96.00 to $103.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Eight equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Establishment Labs has an average rating of “Moderate Buy” and an average target price of $100.25.

Establishment Labs Trading Up 1.6%

Shares of ESTA opened at $72.67 on Friday. The firm has a market capitalization of $2.17 billion, a price-to-earnings ratio of -55.47 and a beta of 1.07. Establishment Labs Holdings Inc. has a 12-month low of $36.53 and a 12-month high of $97.59. The stock’s 50-day moving average price is $86.19 and its 200 day moving average price is $74.84. The company has a quick ratio of 2.52, a current ratio of 3.84 and a debt-to-equity ratio of 12.11.

Establishment Labs (NASDAQ:ESTA) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.05). The business had revenue of $67.54 million for the quarter, compared to analyst estimates of $65.79 million. Establishment Labs had a negative return on equity of 196.69% and a negative net margin of 15.82%.The firm’s quarterly revenue was up 31.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.57) EPS. As a group, research analysts predict that Establishment Labs Holdings Inc. will post -1.15 earnings per share for the current year.

Establishment Labs Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.